Masoomian Babak, Dalvin Lauren A, Yu Michael D, Stathopoulos Christina, Shields Carol L
Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, 840 Walnut Street, 14th Floor, Philadelphia, PA 19107, United States.
Department of Ophthalmology, Mayo Clinic, Rochester, MN 55905, United States.
Saudi J Ophthalmol. 2019 Jul-Sep;33(3):243-250. doi: 10.1016/j.sjopt.2019.07.008. Epub 2019 Aug 27.
To describe comparative clinical features, treatment, and outcomes of retinoblastoma in patients initially diagnosed at age 4 or older.
Retrospective case series.
There were 101 eyes in 100 consecutive patients age ≥4 years diagnosed with retinoblastoma. Mean patient age at diagnosis was 6.6 years (median 5.3, range 4.0-41.0 years). Tumors were predominantly classified (International Classification of Retinoblastoma) as group D (31%) or E (65%). Patients were divided by age into 3 groups: young (4-6 years [65%]), middle (>6-8 years [23%]), and older (>8 years [12%]). Comparing by age group (young vs. middle vs. older), mean tumor basal diameter (19.9 vs. 17.3 vs. 17.0 mm, = 0.05) and mean tumor thickness (11.0 vs. 9.4 vs. 7.0 mm, < 0.01) were greatest in the youngest group. Distance to the optic nerve (1.5 vs. 1.7 vs. 5.0 mm, = 0.01) and foveola (1.9 vs. 1.8 vs. 6.0 mm, < 0.01) were greatest in the oldest age group. Objective findings of leukocoria and strabismus were more common in younger patients, while older patients complained of subjective findings, like decreased vision (19% vs. 30% vs. 60%, < 0.01) and floaters (3% vs. 4% vs. 17%, = 0.05). Primary treatment included enucleation (76%) and other modalities (24%). Globe salvage rate was 13%, with no significant difference by age. Comparison of globe salvage by revealed significant improvement between 1974-2008 (6%) and 2009-2017 (38%, < 0.01).
Retinoblastoma in older patients (>8 years) tends to be smaller and more peripherally located, with more subjective presenting symptoms.
描述最初在4岁及以上确诊的视网膜母细胞瘤患者的临床特征、治疗方法及预后情况。
回顾性病例系列研究。
100例连续确诊为视网膜母细胞瘤且年龄≥4岁的患者共101只眼。诊断时的平均患者年龄为6.6岁(中位数5.3岁,范围4.0 - 41.0岁)。肿瘤主要(按照视网膜母细胞瘤国际分类法)分为D组(31%)或E组(65%)。患者按年龄分为3组:年轻组(4 - 6岁[65%])、中年组(>6 - 8岁[23%])和老年组(>8岁[12%])。按年龄组比较(年轻组与中年组与老年组),最年轻组的平均肿瘤基底直径最大(19.9 vs. 17.3 vs. 17.0 mm,P = 0.05),平均肿瘤厚度也最大(11.0 vs. 9.4 vs. 7.0 mm,P < 0.01)。老年组到视神经的距离(1.5 vs. 1.7 vs. 5.0 mm,P = 0.01)和到黄斑中心凹的距离(1.9 vs. 1.8 vs. 6.0 mm,P < 0.01)最大。白瞳症和斜视等客观表现较年轻患者更常见,而老年患者则主诉视力下降(19% vs. 30% vs. 60%,P < 0.01)和飞蚊症(3% vs. 4% vs. 17%,P = 0.05)等主观表现。主要治疗方法包括眼球摘除术(76%)和其他治疗方式(24%)。眼球保留率为13%,各年龄组无显著差异。比较不同时期的眼球保留情况发现,1974 - 2008年(6%)与2009 - 2017年(38%,P < 0.01)有显著改善。
老年患者(>8岁)的视网膜母细胞瘤往往较小且更位于周边,主观症状表现更多。